NeuroPace

NeuroPace, Inc. develops, manufactures and markets implantable devices for treating epilepsy and neurological disorders. It offers implantable components which include the RNS neurostimulator as well as depth and cortical strip leads. The firm's product RNS system is designed for the treatment of medically refractory partial epilepsy includes implantable and external products. The company was founded by Robert Fischell, David Fischell, Tim Fischell, Scott Fischell, Rebecca L. Kuhn, Frank M. Fischer and Martha Morrell on November 19, 1997 and is headquartered in Mountain View, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

NeuroPace reports robust Q4 performance and outlines growth strategies

NeuroPace's Q4 call highlighted strong performance, strategic priorities for 2023, and challenges in maintaining gross margins. The company's focus on revenue growth drivers, market recovery, and new center expansions positions it well for future growth.

NeuroPace reports record revenue in Q1 2023, raises full-year guidance

NeuroPace delivered strong revenue growth in Q1 2023, with a positive outlook for the full year. The company faces challenges in managing operating expenses and sustaining profitability. However, opportunities lie in product distribution, clinical trials, and strategic growth initiatives.

NeuroPace excels in Q2, raises revenue guidance amid strategic growth

NeuroPace's Q2 performance reflects strong growth momentum and improved financial health, supported by strategic partnerships and effective expense management. The company's focus on expanding patient access and optimizing sales operations positions it well for continued success in 2023.

NeuroPace reports robust Q3 earnings, eyes strategic growth opportunities

NeuroPace's Q3 performance reflects strong revenue growth, improved margins, and prudent cost management, positioning the company for sustained success.
While facing challenges in net losses and operating expenses, NeuroPace's operational achievements and financial stability provide a solid foundation for future growth.
By addressing cost structures, leveraging market opportunities, and adapting to evolving market dynamics, NeuroPace can enhance profitability and drive long-term value creation.

NeuroPace reports robust revenue growth and strategic collaborations for 2024

NeuroPace's strong performance in Q4 2023 and full-year results demonstrate growth momentum.
Strategic collaborations and a focus on cost management are key strengths.
Challenges include managing expenses and market dynamics, but growth opportunities are present.
Overall, NeuroPace is well-positioned for revenue growth and transformative impact in 2024.

NeuroPace reports strong Q1 revenue growth and strategic collaborations

NeuroPace's Q1 2024 performance reflects revenue growth, margin improvements, and strategic collaborations.
The company faces challenges in maintaining margins, financial discipline, and closing the treatment gap.
Opportunities lie in expanding therapy access, market growth, and executing the growth strategy.
Overall, NeuroPace is on track to drive revenue through product sales and strategic initiatives.

NeuroPace reports robust Q2 earnings, eyes growth through strategic initiatives

NeuroPace's Q2 2024 performance reflects revenue growth, improved gross margin, and strategic initiatives driving future expansion and market penetration.
While facing challenges in managing operating expenses and maintaining margins, the company's strong cash position and growth strategy present opportunities for sustained growth.
Overall, NeuroPace's focus on innovation, market expansion, and financial prudence positions it well for future success in the neurotechnology sector.

NeuroPace reports robust Q3 earnings, eyes growth in epilepsy market

NeuroPace's Q3 2024 performance reflects solid revenue growth, operational improvements, and strategic focus on innovation and market expansion.
While facing challenges such as operating losses and competitive pressures, the company is well-positioned to leverage growth opportunities in the epilepsy treatment market.
With a strong financial position, effective leadership enhancements, and proactive investor engagement, NeuroPace is poised for continued growth and market success.
Strategic initiatives and upcoming events underscore the company's commitment to driving value for stakeholders and advancing its position in the industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NeuroPace, Inc. develops, manufactures, and markets implantable devices for treating epilepsy and neurological disorders. It offers implantable components, which include the RNS neurostimulator as well as depth and cortical strip leads. The firm's RNS System is designed for the treatment of medically refractory partial epilepsy and includes implantable and external products. The company was founded by Rebecca L. Kuhn, Frank M. Fischer on November 19, 1997 and is headquartered in Mountain View, CA.

NeuroPace, Inc. (NASDAQ:NPCE) Q4 2023 Earnings Conference Call March 5, 2024 4:30 PM ET

NeuroPace, Inc. (NPCE) Q4 2023 Earnings Call Transcript

-- Revenue increased to $18.0 million in Q4 2023, a 41% increase over Q4 2022 -- -- Revenue increased to $65.4 million in 2023, a 44% increase over 2022 --

NeuroPace Announces Record Full Year 2023 Revenue of $65.4 Million

Bioceres Crop Solutions Corp

Direct Digital Holdings

One of the best stocks for financial freedom over the past 30 years is Monster Beverage (NASDAQ: MNST ). Between Feb. 14, 1994, and Feb. 14, 2024, the energy drink maker's stock appreciated around 200,000%.

Financial Freedom Fighters: 3 Stocks to Liberate Your Portfolio

MOUNTAIN VIEW, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the fourth quarter and full year 2023 after market close on Tuesday, March 5, 2024. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

NeuroPace to Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024

Preliminary unaudited revenue expected to be between $17.5 million and $18.0 million for Q4 2023 and between $64.9 million and $65.4 million for full year 2023

NeuroPace Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2023 and Provides Business Updates

NAUTILUS is the first and only pivotal clinical study to evaluate neuromodulation therapy for treating drug refractory idiopathic generalized epilepsy

NeuroPace Announces Early Completion of Patient Enrollment in NAUTILUS Pivotal Study

MOUNTAIN VIEW, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will present at the 42nd Annual J.P. Morgan Healthcare Conference at 7:30am PT (10:30am ET) on Thursday, January 10, 2024, in San Francisco, CA as well as host investor meetings prior to and during the conference.

NeuroPace to Present at the 42nd Annual J.P. Morgan Healthcare Conference

First of its kind, multi-year collaboration leverages RNS System's data to track responses of implanted RNS System patients enrolled in a biotechnology company's clinical trial

NeuroPace to Leverage the Power of its RNS System's Novel Data Collection, Brain Monitoring and Analysis Capabilities in Groundbreaking Collaboration

MOUNTAIN VIEW, Calif., Dec. 01, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced that the Company will have a substantial presence at the 77th American Epilepsy Society Annual Meeting (AES 2023), to be held in Orlando, Florida and virtually from December 1-5, 2023.

NeuroPace and the RNS System Showcased at the 77th American Epilepsy Society (AES) Annual Meeting

MOUNTAIN VIEW, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced will present at the Piper Sandler 35th Annual Healthcare Conference, taking place November 28-30 in New York, NY.

NeuroPace to Present at the Piper Sandler 35th Annual Healthcare Conference

NeuroPace, Inc. (NASDAQ:NPCE ) Q3 2023 Earnings Conference Call November 6, 2023 4:30 PM ET Company Participants Irina Ridley - Chief Legal Officer and Head of Investor Relations Joel Becker - Chief Executive Officer Rebecca Kuhn - Chief Financial Officer Conference Call Participants Vik Chopra - Wells Fargo Michael Polark - Wolfe Research Frank Takkinen - Lake Street Capital Markets Operator Ladies and gentlemen, greetings and welcome to the NeuroPace, Inc. Third Quarter 2023 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.

NeuroPace, Inc. (NPCE) Q3 2023 Earnings Call Transcript

Third quarter 2023 revenue of $16.4 million, an increase of 47% year-over-year Full-year revenue guidance increased to $62.5-$63.5 million, up from $59-$61 million Cash burn reduced to $2.2 million in the third quarter of 2023, relative to $4 million in the second quarter of 2023 MOUNTAIN VIEW, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for the third quarter ended September 30, 2023.

NeuroPace Reports Third Quarter 2023 Financial Results and Increases Full Year 2023 Revenue Guidance

- Upgraded nSight Platform Improves Clinicians' Ability to Track, Review and Evaluate Patient Data - - ‘Simple Set Programming' Enables Complete Programming Set Transfer Directly to RNS Tablet - - FDA Approval of Smaller, Portable and Simpler Tablet Remote Monitor with Wireless Connectivity - MOUNTAIN VIEW, Calif., Oct. 17, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced a series of key enhancements to its RNS System, all designed to streamline care.

NeuroPace Announces RNS System Enhancements Designed to Streamline Care

MOUNTAIN VIEW, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the third quarter of 2023 after market close on Monday November 6, 2023. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

NeuroPace to Report Third Quarter 2023 Financial Results on November 6, 2023

MOUNTAIN VIEW, Calif., Sept. 20, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced participation in a fireside chat discussion at the upcoming 2023 Cantor Fitzgerald Global Healthcare Conference on Thursday, September 28, 2023, at 1:15 p.m. ET in New York, New York.

NeuroPace to Participate in 2023 Cantor Fitzgerald Global Healthcare Conference

NeuroPace aims to improve the lives of epilepsy patients with its remote monitoring system. The company's RNS system offers personalized and real-time treatments for epilepsy patients. NeuroPace has seen improved commercial traction and increased sales guidance but still faces significant operating losses and cash burn.

NeuroPace: A Speculative Epilepsy Play

Coinbase

Amidst a backdrop of cautious remarks from Fed Chair Jerome Powell, the US stock market experienced a significant upsurge this week. Investors set aside concerns as they eagerly awaited pivotal inflation and job data scheduled for Thursday and Friday.

Two stocks ‘on fire' today as Wall Street embarks on a buying spree

- Wells Fargo 2023 Healthcare Conference - - Morgan Stanley 21 st Annual Global Healthcare Conference - - Lake Street Capital Markets 7 th Annual Best Ideas Growth Conference - MOUNTAIN VIEW, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced its participation in the following upcoming investor conferences: Management will host 1x1 meetings at the Wells Fargo 2023 Healthcare Conference on Thursday, September 7, 2023, in Everett, MA.

NeuroPace to Participate in Upcoming Investor Conferences

NeuroPace, Inc. (NASDAQ:NPCE ) Q2 2023 Earnings Conference Call August 8, 2023 4:30 PM ET Company Participants Irina Ridley - Chief Legal Officer and Head of Investor Relations Joel Becker - Chief Executive Officer Rebecca Kuhn - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Paige Chamberlain - Wolfe Research Operator Good afternoon and welcome to NeuroPace's Second Quarter 2023 Earnings Conference Call. As a reminder, this conference is being recorded.

NeuroPace, Inc. (NPCE) Q2 2023 Earnings Call Transcript

Second quarter 2023 revenue of $16.5 million increased 62% year-over-year Full-year revenue guidance increased to $59-$61 million, up from $52-54 million Cash burn reduced to $4 million in the second quarter of 2023, relative to $9.8 million in the first quarter of 2023 MOUNTAIN VIEW, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for the second quarter ended June 30, 2023.

NeuroPace Reports Second Quarter 2023 Financial Results and Increases Full Year 2023 Revenue Guidance

MOUNTAIN VIEW, Calif., July 19, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced that it granted to Joel Becker, NeuroPace's recently-appointed Chief Executive Officer and director, an option to purchase 380,424 shares of NeuroPace's common stock at an exercise price of $4.39 under its 2023 Inducement Plan. The award was granted as an inducement material to Mr. Becker becoming a new employee of NeuroPace in accordance with The Nasdaq Stock Market Listing Rule 5635(c)(4).

NeuroPace Announces Inducement Grants Under Listing Rule 5635(c)(4) of The Nasdaq Stock Market

MOUNTAIN VIEW, Calif., July 18, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the second quarter of 2023 after market close on Tuesday August 8, 2023. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

NeuroPace to Report Second Quarter 2023 Financial Results on August 8, 2023

NeuroPace Appoints Joel Becker as President & CEO Becker Brings a Track Record of Strong Commercial Execution and Deep Medical Device Operating Expertise Mike Favet to leave Company after four years as President, CEO and Board Member and will continue to advise through transition MOUNTAIN VIEW, Calif., June 28, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced the appointment of Mr.

NeuroPace Announces CEO Transition

To focus on commercial growth, including expanding adoption and driving higher utilization of NeuroPace's RNS System To focus on commercial growth, including expanding adoption and driving higher utilization of NeuroPace's RNS System

NeuroPace Announces Addition of Kelley Nicholas as Vice President, Sales

NeuroPace, Inc. (NASDAQ:NPCE ) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Company Participants Trip Taylor - Gilmartin Group Michael Favet - President & Chief Executive Officer, NeuroPace, Inc. Rebecca Kuhn - Chief Financial Officer & Vice President, NeuroPace, Inc. Conference Call Participants Rohan - JP Morgan Frank Takkinen - Lake Street Capital Markets Michael Polark - Wolfe Research Operator Good afternoon, and welcome to NeuroPace's First Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode.

News for NeuroPace Stock (NPCE)